Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

MAFLD and risk of CKD

Sun, Dan Qin ; Jin, Yan ; Wang, Ting Yao ; Zheng, Kenneth I. ; Rios, Rafael S. ; Zhang, Hao Yang LU orcid ; Targher, Giovanni ; Byrne, Christopher D. ; Yuan, Wei Jie and Zheng, Ming Hua (2021) In Metabolism: Clinical and Experimental 115. p.1-7
Abstract

Background/aims: Whereas nonalcoholic fatty liver disease (NAFLD) is a multisystem disease, the association between metabolic dysfunction-associated fatty liver disease (MAFLD) and extra-hepatic diseases is not known. The aim of this cross-sectional study was to compare the prevalence of chronic kidney disease (CKD) in patients with either MAFLD or NAFLD, and then to examine the association between the presence and severity of MAFLD and CKD and abnormal albuminuria. Methods: A total of 12,571 individuals with complete biochemical and liver ultrasonography data from the Third National Health and Nutrition Examination Survey (1988–1994) were included in the analysis. Multivariable logistic regression analyses were performed to test the... (More)

Background/aims: Whereas nonalcoholic fatty liver disease (NAFLD) is a multisystem disease, the association between metabolic dysfunction-associated fatty liver disease (MAFLD) and extra-hepatic diseases is not known. The aim of this cross-sectional study was to compare the prevalence of chronic kidney disease (CKD) in patients with either MAFLD or NAFLD, and then to examine the association between the presence and severity of MAFLD and CKD and abnormal albuminuria. Methods: A total of 12,571 individuals with complete biochemical and liver ultrasonography data from the Third National Health and Nutrition Examination Survey (1988–1994) were included in the analysis. Multivariable logistic regression analyses were performed to test the independence of associations between MAFLD or MAFLD severity as the key exposures and CKD (defined as either CKD stage ≥1 or stage ≥3) or abnormal albuminuria (urinary albumin-to-creatinine ratio ≥ 3 mg/mmol) as the outcomes. Results: The prevalence of MAFLD and NAFLD was 30.2% (n = 3794) and 36.2% (n = 4552), respectively. MAFLD individuals had a lower eGFR (74.96 ± 18.21 vs. 76.46 ± 18.24 ml/min/1.73 m2, P < 0.001) and a greater prevalence of CKD (29.60% vs. 26.56%, P < 0.05) than NAFLD individuals. Similarly, there was a higher prevalence CKD in MAFLD than in non-metabolic dysfunction-associated NAFLD (P < 0.05). Notably, after adjustment for sex, age, ethnicity, alcohol intake and diabetes, the severity of MAFLD (i.e. NAFLD fibrosis score ≥ 0.676) was associated with 1.34-fold higher risk of prevalent CKD (P < 0.05). Conclusions: MAFLD identifies patients with CKD better than NAFLD. MAFLD and MAFLD with increased liver fibrosis score are strongly and independently associated with CKD and abnormal albuminuria.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
keywords
Chronic kidney disease, Metabolic dysfunction-associated fatty liver disease, Non-alcoholic fatty liver disease
in
Metabolism: Clinical and Experimental
volume
115
article number
154433
pages
1 - 7
publisher
Elsevier
external identifiers
  • pmid:33212070
  • scopus:85097091914
ISSN
0026-0495
DOI
10.1016/j.metabol.2020.154433
language
English
LU publication?
no
additional info
Publisher Copyright: © 2020 Elsevier Inc.
id
d5c51779-3a6b-44b0-a03f-1c4ad6690704
date added to LUP
2024-02-05 15:44:50
date last changed
2024-04-22 00:00:21
@article{d5c51779-3a6b-44b0-a03f-1c4ad6690704,
  abstract     = {{<p>Background/aims: Whereas nonalcoholic fatty liver disease (NAFLD) is a multisystem disease, the association between metabolic dysfunction-associated fatty liver disease (MAFLD) and extra-hepatic diseases is not known. The aim of this cross-sectional study was to compare the prevalence of chronic kidney disease (CKD) in patients with either MAFLD or NAFLD, and then to examine the association between the presence and severity of MAFLD and CKD and abnormal albuminuria. Methods: A total of 12,571 individuals with complete biochemical and liver ultrasonography data from the Third National Health and Nutrition Examination Survey (1988–1994) were included in the analysis. Multivariable logistic regression analyses were performed to test the independence of associations between MAFLD or MAFLD severity as the key exposures and CKD (defined as either CKD stage ≥1 or stage ≥3) or abnormal albuminuria (urinary albumin-to-creatinine ratio ≥ 3 mg/mmol) as the outcomes. Results: The prevalence of MAFLD and NAFLD was 30.2% (n = 3794) and 36.2% (n = 4552), respectively. MAFLD individuals had a lower eGFR (74.96 ± 18.21 vs. 76.46 ± 18.24 ml/min/1.73 m<sup>2</sup>, P &lt; 0.001) and a greater prevalence of CKD (29.60% vs. 26.56%, P &lt; 0.05) than NAFLD individuals. Similarly, there was a higher prevalence CKD in MAFLD than in non-metabolic dysfunction-associated NAFLD (P &lt; 0.05). Notably, after adjustment for sex, age, ethnicity, alcohol intake and diabetes, the severity of MAFLD (i.e. NAFLD fibrosis score ≥ 0.676) was associated with 1.34-fold higher risk of prevalent CKD (P &lt; 0.05). Conclusions: MAFLD identifies patients with CKD better than NAFLD. MAFLD and MAFLD with increased liver fibrosis score are strongly and independently associated with CKD and abnormal albuminuria.</p>}},
  author       = {{Sun, Dan Qin and Jin, Yan and Wang, Ting Yao and Zheng, Kenneth I. and Rios, Rafael S. and Zhang, Hao Yang and Targher, Giovanni and Byrne, Christopher D. and Yuan, Wei Jie and Zheng, Ming Hua}},
  issn         = {{0026-0495}},
  keywords     = {{Chronic kidney disease; Metabolic dysfunction-associated fatty liver disease; Non-alcoholic fatty liver disease}},
  language     = {{eng}},
  pages        = {{1--7}},
  publisher    = {{Elsevier}},
  series       = {{Metabolism: Clinical and Experimental}},
  title        = {{MAFLD and risk of CKD}},
  url          = {{http://dx.doi.org/10.1016/j.metabol.2020.154433}},
  doi          = {{10.1016/j.metabol.2020.154433}},
  volume       = {{115}},
  year         = {{2021}},
}